Order Article Reprints

Bauckneht M, Genova C, Rossi G, Rijavec E, Dal Bello MG, Ferrarazzo G, Tagliamento M, Donegani MI, Biello F, Chiola S, et al. The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. Cancers. 2021; 13(13):3117. https://doi.org/10.3390/cancers13133117

Bauckneht, Matteo, Carlo Genova, Giovanni Rossi, Erika Rijavec, Maria Giovanna Dal Bello, Giulia Ferrarazzo, Marco Tagliamento, Maria Isabella Donegani, Federica Biello, Silvia Chiola, and et al. 2021. "The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab" Cancers 13, no. 13: 3117. https://doi.org/10.3390/cancers13133117

Bauckneht, M., Genova, C., Rossi, G., Rijavec, E., Dal Bello, M. G., Ferrarazzo, G., Tagliamento, M., Donegani, M. I., Biello, F., Chiola, S., Zullo, L., Raffa, S., Lanfranchi, F., Cittadini, G., Marini, C., Lopci, E., Sambuceti, G., Grossi, F., & Morbelli, S. (2021). The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. Cancers, 13(13), 3117. https://doi.org/10.3390/cancers13133117